Monitor management's ability to offset the permanent loss of $2.5M in annual revenue from PendoTECH and the China distributor with new product sales and organic growth. The stock's recent 11% price increase since year-end may be overestimating the company's recovery potential.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 23 $67.87entry
- T+1 · 7mo ago −1.03%α −1.82% · $67.17
- T+5 · 7mo ago −4.18%α −5.66% · $65.03
- T+20 · 6mo ago −5.45%α −10.09% · $64.17
- T+60 · 4mo ago +2.11%α −2.91% · $69.30
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Utah Medical Products (UTMD) reported Q1 2026 earnings with revenue of $8.72M, down 10.2% YoY, and EPS of $0.818, down 11.0%. The decline was driven by the expected loss of $857K in sales from two former customers (PendoTECH and a China distributor), partially offset by a 47.4% increase in domestic Filshie device sales. Gross margin improved to 60.6% due to favorable product mix and a one-time inventory adjustment.
Key Financial Metrics
Key Facts
- Q1 2026 revenue was $8,722K, down 10.2% from $9,710K in Q1 2025
- EPS was $0.818, down 11.0% from $0.919 in Q1 2025
- Gross margin improved to 60.6% from 57.0% in Q1 2025
- Operating income declined 18.7% to $2,565K
- Loss of $857K in sales from PendoTECH and China distributor accounted for 87% of the revenue decline
- Domestic Filshie device sales increased 47.4% to $493K
- Company repurchased 2,196 shares in Q1 2026 at an average price of $58.58
Financial Impact
Revenue declined $988K (-10.2%) and EPS declined $0.101 (-11.0%) compared to Q1 2025
Risk Factors
- Permanent loss of $2.5M in annual revenue from two key customers
- Increased litigation expenses and U.S. healthcare costs pressured operating expenses
- Management's projection of offsetting lost revenue with new products carries substantial uncertainty
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001096906-26-000602 |
| Document: utmd-20260423_8k.htm | 0001096906-26-000602 |
| Document: 0001096906-26-000602-index-headers.html | 0001096906-26-000602 |
| Document: 0001096906-26-000602-index.html | 0001096906-26-000602 |
| Document: 0001096906-26-000602.txt | 0001096906-26-000602 |
| 8-K Data (Synthetic) | 0001096906-26-000602 |
Track record
11 reports on UTMD
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 3, 202613d ago 8-K Neutral 2/10 Entry $70.02 Now $72.36 +3.34% settles Dec 2
- Oct 29, 202618d ago Insider Buy Neutral 3/10 Entry $68.08 Now $72.36 +6.29% settles Nov 30
- Oct 29, 202618d ago SC TO-I/A Neutral 4/10 Entry $66.80 Now $72.36 +8.32% settles Nov 27
- Oct 22, 202625d ago 8-K Mixed 5/10 Entry $75.06 Now $72.36 −3.60% settles Nov 19
- Oct 5, 20266w ago SC TO-I/A Neutral 3/10 Entry $73.31 to $68.08 Now $72.36 −1.30% ▼ −7.14% −4.67% vs SPY
- Sep 25, 20267w ago SC TO-C Neutral 2/10 Entry $74.18 to $74.23 Now $72.36 −2.45% ▲ +0.07% +1.54% vs SPY
- Sep 24, 20267w ago SC TO-C Mixed 6/10 Entry $74.18 to $74.23 Now $72.36 −2.45% ▲ +0.07% +1.54% vs SPY
- Sep 23, 20267w ago SC TO-I Mixed 5/10 Entry $74.75 to $75.06 Now $72.36 −3.20% ▲ +0.41% +0.83% vs SPY
- Aug 31, 202611w ago 8-K Bullish 5/10 Entry $71.13 to $74.95 Now $72.36 +1.73% ▲ +5.37% +5.56% vs SPY
- Jul 23, 202616w ago 8-K Bearish 7/10 Entry $64.18 to $71.42 Now $72.36 −12.75% ▼ −11.28% −7.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers